A Study of LY3437943 in Participants Who Have Obesity or Are Overweight
Completed · Phase 2 · NCT04881760
Conditions: Obesity, Overweight
At a glance
- Research payments reported, 2025
- $108,117
- U.S. investigators named
- 2
- Sites paid
- 1
- Planned or actual enrollment
- 338
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY3437943 (drug), Placebo (drug)
- Dates
- Started 2021-05-20; completion 2022-11-22
- Results posted
- Yes
This is a study of LY3437943 in participants who have obesity or are overweight. The main purpose is to learn more about how LY3437943 affects body weight loss. The study will last about 18 months and may include up to 18 visits.
From ClinicalTrials.gov, last updated 2023-09-13. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $108,117 in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Juan P. Frias, M.D. Endocrinology & Diabetes · San Diego, CA
- Stanley Hsia, M.D. Endocrinology & Diabetes · Los Angeles, CA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Velocity Clinical Research Inc $108,117
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.